Key Highlights

  • Shares are trading down 7.63% to $9.20, underperforming the broader healthcare sector.
  • The decline follows strong second-quarter momentum, with Revenue up 34% year over year.
  • The company raised its full-year 2026 guidance to $690 million to $715 million on Orladeyo strength and Navenibart licensing revenue.
  • Risk-off sentiment is sweeping the market amid surging oil prices, escalating U.S.-Iran tensions, and rising Fed rate-hike expectations ahead of next week's FOMC meeting.
  • Peers including Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are also falling today.

Shares Slide Despite Raised Guidance

A NASDAQ-listed biotechnology company is trading sharply lower today despite raising its full-year guidance following a strong quarter, an outcome that would typically be read as good news for the stock. BioCryst Pharmaceuticals (NASDAQ:BCRX) is underperforming the broader healthcare sector even after reporting a beat-and-raise second quarter, with revenue up 34% year over year, driven by strength in its commercial product Orladeyo and Navenibart licensing revenue.

Guidance Raised on Orladeyo and Navenibart Strength

The company raised its full-year 2026 guidance to $690 million to $715 million, reflecting continued strength in Orladeyo, its once-daily oral plasma kallikrein inhibitor approved for prophylactic treatment of hereditary angioedema, alongside licensing revenue from Navenibart, its Phase 3 candidate also being developed for the condition.

Macro Pressure Appears to Explain the Decline

Today's decline appears driven more by macro and risk-off sentiment sweeping the broader biotech and healthcare sector than by any company-specific news, as investors weigh surging oil prices, escalating U.S.-Iran tensions, and rising Fed rate-hike expectations ahead of next week's FOMC meeting. Peers including Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are also falling today, with the broader healthcare index (XLV) trading lower as well.

Underlying Business Fundamentals Remain Strong

BioCryst's underlying business, anchored by Orladeyo and supported by a pipeline including navenibart and BCX17725 for Netherton syndrome, appears unaffected by today's decline, suggesting the pullback reflects broader de-risking rather than any deterioration in company fundamentals. Continued execution on the raised full-year guidance will likely be the key Factor supporting the stock once the current risk-off tone eases.